SOLNA, Sweden - 16 April, 2014 - Aerocrine AB (OMX Nordic Exchange: AERO)
announces that the annual report 2013 has been published.
The complete annual report can be found on the Company website. See link below:
För more information, contact:
Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379, +970
Michael Colérus, CFO Aerocrine AB, Phone: + 46 70 341 34 72
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO® (EU) Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm
Stock Exchange in 2007. For more information, please visit www.aerocrine.com and
Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication on 04/16/2014 at 5.00 p.m.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.